Researchers at the University of Queensland have introduced a novel evaluation framework designed to enhance the transparency and reliability of artificial intelligence in antibiotic discovery, directly addressing the escalating global threat of antimicrobial resistance. Published in the Journal of Cheminformatics, the study targets the persistent challenge of the AI black box problem in pharmaceutical development, where predictive models generate compound recommendations without providing chemically understandable reasoning. Dr. Abdulmujeeb Onawole and Dr. Johannes Zuegg from the university Center for Superbug Solutions emphasize that this lack of interpretability has historically hindered medicinal chemists from trusting AI driven suggestions, often resulting in wasted laboratory resources and delayed treatments. To resolve this, the research team engineered a testing protocol that evaluates whether AI systems can accurately identify critical drug structures and interpret activity cliffs, scenarios where minor molecular modifications significantly alter a compounds efficacy. The framework was applied to three distinct AI models trained on historical chemical datasets targeting Staphylococcus aureus, a leading multidrug resistant pathogen. While all models demonstrated proficiency in recognizing established antibiotic architectures, their capacity to generate reliable chemical explanations varied considerably. The framework successfully distinguished between models offering scientifically valid insights and those producing misleading or unsubstantiated predictions. This capability represents a critical advancement for integrating machine learning into high stakes drug development pipelines. By filtering out unreliable AI outputs and validating chemically sound reasoning, the tool empowers researchers to make informed experimental decisions without compromising laboratory efficiency. Long term, this transparent evaluation methodology is expected to accelerate the identification of novel therapeutic compounds, directly contributing to global efforts to combat superbugs. The development marks a strategic step toward operationalizing AI as a trustworthy partner in overcoming antimicrobial resistance, ensuring that computational predictions align with established pharmacological principles before advancing to clinical phases.